We don’t follow footsteps. We create the path.

News & events

LUXTURNA Achieves European Approval Marketing authorization granted by the European Commission

Read More read more

Q3 2018 earnings Spark Therapeutics reports Q3 2018 financial results and recent business highlights

Read More read more

Preclinical Data for Pompe Disease Program Spark Therapeutics announces new preclinical data for Pompe disease investigational gene therapy candidate

Read More read more

Get our news alerts delivered straight to your inbox

Subscribe Now

We don’t follow footsteps. We create the path.

Our mission at Spark Therapeutics is to challenge the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable—until now. We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations. Find out more about how we strive to turn genes into medicines for patients with inherited diseases, including inherited retinal diseases (IRDs), liver-directed diseases such as hemophilia, and neurodegenerative diseases.

Learn More